| Market Cap | 18.25M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -2.88M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -48.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -48.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -73.00% |
| Recommedations | - | Quick Ratio | 0.15 | Shares Outstanding | 91.27M | 52W Low Chg | 67.00% |
| Insider Own | 45.03% | ROA | -204.29% | Shares Float | 50.45M | Beta | 0.65 |
| Inst Own | 1.12% | ROE | - | Shares Shorted/Prior | 2.03M/2.08M | Price | 0.20 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 149,765 | Target Price | 10.25 |
| Oper. Margin | - | Earnings Date | Aug 15 | Volume | 881,574 | Change | 0.00% |
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.